HC Wainwright & Co. reiterated coverage on BiomX with a new price target
$PHGE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously